Protease inhibitor resistance involves multiple stages of the HIV-1 life cycle

HIV-1 protease inhibitors are very effective antiviral drugs. These drugs target HIV-1 proteases, which are required for viral replication. Despite the success of protease inhibitors for suppressing HIV-1, some patients do not respond to protease inhibitor therapy. For most patients, the lack of response is not due to mutation of the HIV-1 protease.

In this issue of the Journal of Clinical Investigation, Robert Silcano and colleagues at Johns Hopkins University identify the effects of protease inhibitors on different stages of viral replication. The authors found that protease inhibitors do not prevent virus release from infected cells, but do prevent viral entry into new cells, and have an effect on the reverse transcription and post-transcription stages of the HIV-1 life cycle.

Additionally, mutations in the viral , which is involved in cell entry, were associated with resistance to protease inhibitor treatment. In the accompanying Attending Physician article, John Bartlett of Duke University discusses how these findings may dictate testing for HIV-1 envelope mutations in patients that have not responded to treatment with .

More information: Multi-step inhibition explains HIV-1 protease inhibitor pharmacodynamics and resistance, J Clin Invest. 2013;123(9):3848–3860. DOI: 10.1172/JCI67399
Lack of protease inhibitor resistance following treatment failure—too good to be true? J Clin Invest. 2013;123(9):3704–3705. DOI: 10.1172/JCI71784

add to favorites email to friend print save as pdf

Related Stories

Anti-HIV drugs reduce the cause of some forms of vision loss

May 23, 2008

A potential new therapeutic use for anti-HIV drugs known as protease inhibitors has been suggested by a team of researchers from Harvard Medical School, Boston, and Inserm U848, France, as a result of their work in a mouse ...

Mathematical models to better combat HIV

May 31, 2013

The first few hours to days following exposure to human immunodeficiency virus (HIV) can be of critical importance in determining if infection occurs in a patient. But the low numbers of viruses and infected cells at this ...

Recommended for you

Long acting HIV drugs to be developed

Sep 11, 2014

HIV drugs which only need to be taken once a month are to be developed at the University of Liverpool in a bid to overcome the problem of 'pill fatigue'.

Puerto Rico partners on US HIV vaccine project

Sep 10, 2014

Puerto Rico's governor says the island's largest public university is partnering with federal agencies to oversee a U.S.-funded project aimed at trying to develop a prophylactic vaccine for the HIV virus that causes AIDS.

User comments